#United States #Austin, Texas #oncology #Genprex #Reqorsa

Genprex Expands Intellectual Property Portfolio

Genprex, Inc., a pioneering company in clinical-stage gene therapy, has recently indicated significant advancements in its intellectual property. With a focus on developing transformative treatments for cancers and diabetes, the company has secured patents in Japan and the European Union for its Reqorsa® gene therapy, which is designed to be combined with groundbreaking immunotherapies to combat cancer. This achievement reinforces Genprex's commitment to providing innovative solutions for patients suffering from aggressive cancer types including small cell lung cancer (SCLC).

Significant Patent Grants

The Japanese Patent Office has made a favorable decision, granting a patent that presents the use of Reqorsa® in conjunction with PD-L1 antibodies to treat cancer. Concurrently, the European Patent Office has granted a similar patent concerning the use of Reqorsa® in combination with PD-1 antibodies. These strategic accomplishments are instrumental in bolstering Genprex's intellectual property framework, granting exclusive rights to crucial therapeutic combinations, particularly in relation to the Acclaim-3 clinical trial involved in treating SCLC.

Thomas Gallagher, the Senior Vice President of Intellectual Property and Licensing at Genprex, highlighted the importance of these decisions, stating, *"These patents validate our innovative approach to cancer treatment and will solidify our global intellectual property portfolio."

Acclaim-3 Clinical Trial Insights

The Acclaim-3 study represents a pivotal Phase 1/2 clinical trial designed to evaluate the efficacy of Reqorsa® coupled with Genentech's Tecentriq® (atezolizumab). This combination is targeted specifically at patients diagnosed with extensive stage small cell lung cancer who are suitable for maintenance therapy following standard initial treatments.

In this study, participants will receive both Reqorsa® and Tecentriq® until the disease progresses or unacceptable side effects occur. The Phase 1 part of the trial indicated that the therapy was generally well tolerated, with no dose-limiting toxicities reported. Following this, the Phase 2 trial is expected to involve around 50 patients, aiming to assess the 18-week progression-free survival rate, an essential measure of treatment effectiveness.

As Geneprx looks towards future enrollment in the first half of 2026, they plan to conduct an interim analysis after treating 25 patients. Support from the FDA through its Fast Track Designation and Orphan Drug Designation also bolsters the importance of this trial in the wider oncology field.

Overview of Genprex, Inc.

Genprex, Inc. stands at the forefront of gene therapy innovations, focusing on developing therapies aimed at changing the lives of patients afflicted with cancers and conditions such as diabetes. With a commitment to harnessing advanced technologies, Genprex's approach encompasses the Oncoprex® Delivery System, a non-viral method that encapsulates essential gene-expressing plasmids employing lipid-based nanoparticles.

The primary product candidate, Reqorsa® Gene Therapy, is being actively tested in several clinical trials for various lung cancer indications. Each of these endeavors reflects Genprex's dedication to addressing the pressing medical needs of patients who often have limited treatment alternatives. The company's diabetes therapy also operates on a novel infusion technique designed to deliver vital genes directly to the pancreas, further highlighting the breadth of their innovative programs.

Final Thoughts

As Genprex continues to solidify its presence in the gene therapy market, the recent patent grants significantly enhance its ability to protect its innovative therapies, particularly in regions crucial for cancer treatment advancements. Investors and stakeholders are encouraged to stay informed on Genprex's progress and developments, reinforcing its role as a leader in the evolution of treatment options for challenging disease states.